• 1
    Morens DM, Fauci AS. Dengue and hemorrhagic fever. A potential threat to public health in the United States. JAMA 2008; 299:214216.
  • 2
    World Health Organization, 2011. Global alert and response: impact of dengue. Available at: (Accessed 2013 Jul 18).
  • 3
    Wilder-Smith A, Schwartz E. Dengue in travelers. N Engl J Med 2005; 353:924932.
  • 4
    Wilson ME, Weld LH, Boggild B, et al. Fever in returned travelers: results from the GeoSentinel Surveillance Network. Clin Infect Dis 2007; 44:15601568.
  • 5
    Ashley EA. Dengue fever. Curr Anaesth Crit Care 2011; 1:3941.
  • 6
    Ooi EE, Goh KT, Gubler DJ. Dengue prevention and 35 years of vector control in Singapore. Emerg Infect Dis 2006; 12:887893.
  • 7
    Horstic O, Runge-Ranzinger S, Nathan MB, Kroeger A. Dengue vector-control services: how do they work? A systematic literature review and country case studies. Trans R Soc Trop Med Hyg 2010; 104:379386.
  • 8
    Guzman MG, Halstead SB, Artsob H, et al. Dengue: a continuing global threat. Nat Rev Microbiol 2010; 8:S7S16.
  • 9
    Schmitz J, Roehrig J, Barrett A, Hombach J. Next generation dengue vaccines: a review of candidates in preclinical development. Vaccine 2011; 29:72767284.
  • 10
    Wilder-Smith A, Deen JL. Dengue vaccines for travelers. Expert Rev Vaccines 2008; 7:569578.
  • 11
    Hill DR, Wilder-Smith A. Travel vaccines: current practice and future aspects. Expert Rev Vaccines 2008; 7:527530.
  • 12
    Brewer NT, Fazekas KI. Predictors of HPV vaccine acceptability: a theory-informed systematic review. Prev Med 2007; 45(2–3):107114.
  • 13
    Zimet GD, Mays RM, Winston Y, et al. Acceptability of human papillomavirus immunization. J Womens Health Gend Based Med 2007; 9:4750.
  • 14
    Rosenthal SL, Kottenhahn RK, Biro FM, Succop PA. Hepatitis B vaccine acceptance among adolescents and their parents. J Adolesc Health 1995; 17:248254.
  • 15
    Lu P, Euler GL, Jumaan AO, Harpaz R. Herpes zoster vaccination among adults aged 60 years or older in the United States, 2007: uptake of the first new vaccine to target seniors. Vaccine 2009; 27:882887.
  • 16
    Miller BL, Kretsinger K, Euler GL, et al. Barriers to early uptake of tetanus, diphtheria and acellular pertussis vaccine (Tdap) among adults—United States, 2005–2007. Vaccine 2011; 29:38503856.
  • 17
    Vitek WS, Akers A, Meyn LA, et al. Vaccine eligibility and acceptance among ambulatory obstetric and gynecologic patients. Vaccine 2011; 29:20242028.
  • 18
    Shepard DS, Suaya JA, Halstead SB, et al. Cost-effectiveness of a pediatric dengue vaccine. Vaccine 2004; 22(9–10):12751280.
  • 19
    DeRoeck D, Deen J, Clemens JD. Policymakers' views on dengue fever/dengue haemorrhagic fever and the need for dengue vaccines in four southeast Asian countries. Vaccine 2003; 22:121129.
  • 20
    Amarasinghe A, Wichmann O, Margolis HS, Mahoney RT. Forecasting dengue vaccine demand in disease endemic and non-endemic countries. Hum Vaccin 2010; 6:745753.
  • 21
    Lown B, Chen LH, Han P, et al. Characteristics, preferences, and decision needs of travelers to countries with risk of yellow fever. Presented at the 13th Conference of the International Society of Travel Medicine; 2013 May 21, Maastricht, Netherlands.
  • 22
    Centers for Disease Control and Prevention. The pre-travel consultation: Japanese encephalitis. In: Brunette GW, ed. Health Information for International Travel 2010. Edinburgh: Mosby, 2009:7481.
  • 23
    Stanton BF. Assessment of relevant cultural considerations is essential for the success of a vaccine. J Health Popul Nutr 2004; 22:286292.
  • 24
    Gust DA, Strine TW, Maurice A, et al. Underimmunization among children: effects of vaccine safety concerns on immunization status. Pediatrics 2004;114:e16e22.
  • 25
    Petty TJ, Callahan ST, Chen Q, et al. Assessment of parental acceptance of a potential cytomegalovirus vaccine for adolescent females. Vaccine 2010; 28:56865690.
  • 26
    Bednarczyk RA, Birkhead RS, Morse DL, et al. Human papillomavirus vaccine uptake and barriers: association with perceived risk, actual risk and race/ethnicity among female students at a New York State University, 2010. Vaccine 2011; 29:31383143.
  • 27
    Lown BA, Chen LH, Wilson ME, et al. Vaccine administration decision-making: the case of yellow fever vaccine. Clin Infect Dis 2012; 55:837843.
  • 28
    Sabchareon A, Wallace D, Sirivichayakul C, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled, phase 2b trial. Lancet 2012 S0140-6736(12)61427-61428.
  • 29
    Ryan M, Gerard K. Using discrete choice experiments to value health care programmes: current practice and future research reflections. Appl Health Econ Health Policy 2003; 2:5564.